UNITED STATES OF AMERICA —Biotechnology venture firm Samsara BioCapital has invested in Redwood City-based R1 Therapeutics, elevating the developer's total Series A capital raised to $80.5 million. The expansion follows an initial $77.5 million financing round finalized in early 2026. R1 Therapeutics is a clinical-stage biopharmaceutical organization focused on discovering and developing novel treatments for renal conditions, primarily advancing therapies that address unmet therapeutic needs in kidney diseases.
The newly secured capital is earmarked to propel the clinical progression of AP306, a monotherapy currently undergoing global Phase 2b clinical evaluation. Designed to treat hyperphosphatemia in patients with chronic kidney disease on dialysis, AP306 operates as a first-in-class pan phosphate transporter inhibitor that targets active transport mechanisms across three gut-level transporters. Topline data from the multi-center, double-blind study—conducted across sites in the United States and China alongside partner Alebund Pharmaceuticals—is anticipated during the first half of 2027.
Elevated serum phosphate remains a critical issue for dialysis patients, with standard-of-care binder therapies frequently failing to control phosphate levels effectively over decades of clinical use. Persistent hyperphosphatemia correlates directly with severe cardiovascular and skeletal complications, as well as higher mortality rates. By targeting active transport rather than relying on conventional binding agents, AP306 offers a novel mechanistic pathway that aims to lower systemic phosphate levels while significantly decreasing patient pill burden.
The arrival of specialized biopharmaceutical investors prior to pivotal clinical readouts underscores growing venture interest in late-stage renal asset pipelines. If successful, active phosphate transport inhibition could redefine nephrology treatment protocols and capture market share from traditional binder products. The continuation of joint trials in Asia and North America further demonstrates an increasing reliance on cross-border clinical operations to optimize trial recruitment and expedite regulatory milestones in specialized therapeutic markets.
